Kirby Daniel Gordon 4

What Happened

• Daniel Gordon, Chief Commercial Officer of Iovance Biotherapeutics (IOVA), had 39,996 restricted stock units (RSUs) vest on February 10, 2026. The RSUs converted to common stock (exercise/conversion of derivative).
• To satisfy mandatory tax withholding, 16,450 shares were withheld by the issuer at an implied value of $2.60 per share (total value withheld $42,770). After withholding, Gordon received a net 23,546 shares.
• This was a vesting/conversion and tax-withholding transaction — not an open-market sale or a cash purchase.

Key Details

• Transaction date: 2026-02-10; Form 4 filed 2026-02-12 (appears timely).
• RSUs converted: 39,996 shares; shares withheld for taxes: 16,450 @ $2.60 = $42,770; net shares delivered: 23,546.
• Codes: M = exercise/conversion of derivative (RSU vesting); F = shares withheld to satisfy tax liability (not an open-market sale).
• Footnotes: each RSU equals one share; remaining RSUs from the Feb 10, 2025 grant will vest in equal quarterly installments; the withheld shares reflect mandatory tax withholding, not a sale.

Context

• This is a routine executive compensation event (vesting of RSUs) rather than a purchase or deliberate sale. Share withholding for taxes is common and does not imply market selling by the insider.
• For retail investors, purchases or open-market insider buys are generally more informative about conviction; this filing documents issuance and withholding arising from compensation.